Scotland launches a two-year newborn SMA screening pilot, adding SMA to the standard blood spot test taken around day four after birth, making Scotland the first UK region to screen all newborns for SMA.

SMA affects about three to four babies per year in Scotland, with the pilot aiming to screen all newborns in the region.

The pilot seeks to determine whether pre-symptomatic detection and early treatment can improve outcomes for children with SMA.

Families and SMA advocates describe the potential for better outcomes and reduced anxiety by catching SMA early.

Stakeholders call the program a historic, game-changing step that could set a precedent for the rest of the UK.

Dr. Sarah Smith explains the test will identify SMA before symptoms appear so treatment can begin early to prevent irreversible damage and improve quality of life.

The Glasgow screening lab will add SMA to its existing panel and enable pre-symptomatic identification followed by treatment.

Health Secretary Neil Gray highlights early detection as potentially life-changing, thanking SMA UK, campaigners, and Novartis for their roles.

Campaigners and SMA UK leadership view the Scotland pilot as a milestone that could drive wider adoption in the UK and improve long-term outcomes.

Parents of a child with SMA describe the impact of the condition and advocate for timely screening and treatment to spare others prolonged anxiety and delays.

Public figures and advocacy groups, including Jesy Nelson, support universal newborn SMA screening, underscoring ongoing public engagement.

The two-year pilot is funded by the Scottish Government and Novartis, totaling about 530,000 pounds.